117 related articles for article (PubMed ID: 7783120)
1. Use of medium-sized cycloalkyl rings to enhance secondary binding: discovery of a new class of human immunodeficiency virus (HIV) protease inhibitors.
Romines KR; Watenpaugh KD; Tomich PK; Howe WJ; Morris JK; Lovasz KD; Mulichak AM; Finzel BC; Lynn JC; Horng MM
J Med Chem; 1995 May; 38(11):1884-91. PubMed ID: 7783120
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors.
Thaisrivongs S; Janakiraman MN; Chong KT; Tomich PK; Dolak LA; Turner SR; Strohbach JW; Lynn JC; Horng MM; Hinshaw RR; Watenpaugh KD
J Med Chem; 1996 Jun; 39(12):2400-10. PubMed ID: 8691434
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design of novel HIV protease inhibitors: carboxamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent nonpeptidic inhibitors.
Thaisrivongs S; Watenpaugh KD; Howe WJ; Tomich PK; Dolak LA; Chong KT; Tomich CC; Tomasselli AG; Turner SR; Strohbach JW
J Med Chem; 1995 Sep; 38(18):3624-37. PubMed ID: 7658450
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease.
Mazumder A; Wang S; Neamati N; Nicklaus M; Sunder S; Chen J; Milne GW; Rice WG; Burke TR; Pommier Y
J Med Chem; 1996 Jun; 39(13):2472-81. PubMed ID: 8691444
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design of nonpeptidic HIV protease inhibitors from a cyclooctylpyranone lead structure.
Romines KR; Watenpaugh KD; Howe WJ; Tomich PK; Lovasz KD; Morris JK; Janakiraman MN; Lynn JC; Horng MM; Chong KT
J Med Chem; 1995 Oct; 38(22):4463-73. PubMed ID: 7473573
[TBL] [Abstract][Full Text] [Related]
6. Potent human immunodeficiency virus type 1 protease inhibitors that utilize noncoded D-amino acids as P2/P3 ligands.
Jungheim LN; Shepherd TA; Baxter AJ; Burgess J; Hatch SD; Lubbehusen P; Wiskerchen M; Muesing MA
J Med Chem; 1996 Jan; 39(1):96-108. PubMed ID: 8568831
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships of some 3-substituted-4-hydroxycoumarins as HIV-1 protease inhibitors.
Kirkiacharian S; Thuy DT; Sicsic S; Bakhchinian R; Kurkjian R; Tonnaire T
Farmaco; 2002 Sep; 57(9):703-8. PubMed ID: 12385519
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors incorporating aminothiochromane and aminotetrahydronaphthalene carboxamide derivatives as the P2 ligands.
Ghosh AK; Jadhav RD; Simpson H; Kovela S; Osswald H; Agniswamy J; Wang YF; Hattori SI; Weber IT; Mitsuya H
Eur J Med Chem; 2018 Dec; 160():171-182. PubMed ID: 30340140
[TBL] [Abstract][Full Text] [Related]
9. Cycloalkylpyranones and cycloalkyldihydropyrones as HIV protease inhibitors: exploring the impact of ring size on structure-activity relationships.
Romines KR; Morris JK; Howe WJ; Tomich PK; Horng MM; Chong KT; Hinshaw RR; Anderson DJ; Strohbach JW; Turner SR; Mizsak SA
J Med Chem; 1996 Sep; 39(20):4125-30. PubMed ID: 8831779
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors.
Thaisrivongs S; Romero DL; Tommasi RA; Janakiraman MN; Strohbach JW; Turner SR; Biles C; Morge RR; Johnson PD; Aristoff PA; Tomich PK; Lynn JC; Horng MM; Chong KT; Hinshaw RR; Howe WJ; Finzel BC; Watenpaugh KD
J Med Chem; 1996 Nov; 39(23):4630-42. PubMed ID: 8917652
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, X-ray crystallography, and infected T-cell assays.
Dreyer GB; Lambert DM; Meek TD; Carr TJ; Tomaszek TA; Fernandez AV; Bartus H; Cacciavillani E; Hassell AM; Minnich M
Biochemistry; 1992 Jul; 31(29):6646-59. PubMed ID: 1637805
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.
Ghosh AK; Takayama J; Kassekert LA; Ella-Menye JR; Yashchuk S; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
Bioorg Med Chem Lett; 2015 Nov; 25(21):4903-4909. PubMed ID: 26096678
[TBL] [Abstract][Full Text] [Related]
13. The development of cyclic sulfolanes as novel and high-affinity P2 ligands for HIV-1 protease inhibitors.
Ghosh AK; Lee HY; Thompson WJ; Culberson C; Holloway MK; McKee SP; Munson PM; Duong TT; Smith AM; Darke PL
J Med Chem; 1994 Apr; 37(8):1177-88. PubMed ID: 8164260
[TBL] [Abstract][Full Text] [Related]
14. Nonpeptidic potent HIV-1 protease inhibitors: (4-hydroxy-6-phenyl-2-oxo-2H- pyran-3-yl)thiomethanes that span P1-P2' subsites in a unique mode of active site binding.
Prasad JV; Para KS; Tummino PJ; Ferguson D; McQuade TJ; Lunney EA; Rapundalo ST; Batley BL; Hingorani G; Domagala JM
J Med Chem; 1995 Mar; 38(6):898-905. PubMed ID: 7699705
[TBL] [Abstract][Full Text] [Related]
15. Aminodiol HIV protease inhibitors. 1. Design, synthesis, and preliminary SAR.
Barrish JC; Gordon E; Alam M; Lin PF; Bisacchi GS; Chen P; Cheng PT; Fritz AW; Greytok JA; Hermsmeier MA
J Med Chem; 1994 Jun; 37(12):1758-68. PubMed ID: 8021916
[TBL] [Abstract][Full Text] [Related]
16. 5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.
Boyer FE; Vara Prasad JV; Domagala JM; Ellsworth EL; Gajda C; Hagen SE; Markoski LJ; Tait BD; Lunney EA; Palovsky A; Ferguson D; Graham N; Holler T; Hupe D; Nouhan C; Tummino PJ; Urumov A; Zeikus E; Zeikus G; Gracheck SJ; Sanders JM; VanderRoest S; Brodfuehrer J; Iyer K; Sinz M; Gulnik SV
J Med Chem; 2000 Mar; 43(5):843-58. PubMed ID: 10715152
[TBL] [Abstract][Full Text] [Related]
17. Paracyclophanes: a novel class of water-soluble inhibitors of HIV proteinase.
Ettmayer P; Billich A; Hecht P; Rosenwirth B; Gstach H
J Med Chem; 1996 Aug; 39(17):3291-9. PubMed ID: 8765512
[TBL] [Abstract][Full Text] [Related]
18. A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease.
Sham HL; Zhao C; Stewart KD; Betebenner DA; Lin S; Park CH; Kong XP; Rosenbrook W; Herrin T; Madigan D; Vasavanonda S; Lyons N; Molla A; Saldivar A; Marsh KC; McDonald E; Wideburg NE; Denissen JF; Robins T; Kempf DJ; Plattner JJ; Norbeck DW
J Med Chem; 1996 Jan; 39(2):392-7. PubMed ID: 8558507
[TBL] [Abstract][Full Text] [Related]
19. A symmetric inhibitor binds HIV-1 protease asymmetrically.
Dreyer GB; Boehm JC; Chenera B; DesJarlais RL; Hassell AM; Meek TD; Tomaszek TA; Lewis M
Biochemistry; 1993 Jan; 32(3):937-47. PubMed ID: 8422397
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands.
Ghosh AK; Sean Fyvie W; Brindisi M; Steffey M; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
Bioorg Med Chem Lett; 2017 Nov; 27(21):4925-4931. PubMed ID: 28958624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
